Global competition is the wrong strategic lens for an industrial policy involving critical collective health needs. Threats to US health and national security interests in this sector are transnational, and the inputs required for US biopharmaceutical innovation and resilience are globally distributed. To accelerate innovation in the life sciences, the US needs a targeted strategy that invests in domestic self-sufficiency where it is attainable and important and that mobilizes the international collaborations needed to make and deploy medical technologies to promote human health and a more resilient economy worldwide. The US needs an industrial policy for global health.
Keywords: China; Global Health; Medical devices; competition; industrial policy; pharmaceuticals; research and development; technology transfer; trade.